Significant advancements in gene silencing and gene editing offer new hope for treating rare disorders. Techniques like RNA ...

Endocrine therapy typically slows cell cycle progression by reducing cyclin D1, which partners with CDK4/6 to promote cell ...

The company says the system can benefit pharmaceutical and biotech firms seeking rapid feedback on drug candidates or genome editing.

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

Two new studies from Mount Sinai’s Living Brain Project reveal that living human brain tissue shows major molecular ...

Foghorn to host a virtual investor event on updates for its Selective ARID1B, Selective CBP and Selective EP300 degrader programs on Thursday October 30, 2025, at 12 p.m. EDTCAMBRIDGE, Mass., Oct. 16, ...

Results of a study led by researchers at Roswell Park Comprehensive Cancer Center are shedding light on why some newly ...

Patients with rheumatoid arthritis increased their leg muscle volume when treated with an anti-rheumatic drug, offering new ...

Lissencephaly are born with a brain in which the typical furrows and convolutions are severely reduced or completely absent.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal ...

In a Melbourne lab, researchers infected male mice with SARS-CoV-2, the virus that causes COVID-19. After the mice recovered, ...

Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by ...